^
Association details:
| Biomarker: | PD-L1 underexpression |
|---|---|
| Cancer: | Cutaneous T-cell Lymphoma |
| Drug: | Imfinzi (durvalumab) (PD-L1 inhibitor) + lenalidomide (TNFα inhibitor, IL-6 inhibitor, IL-12 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase 1 Results of Anti-PD-Ligand 1 (Durvalumab) & Lenalidomide in Patients with Cutaneous T Cell Lymphoma and Correlation with Programmed Death Ligand 1 Expression and Gene Expression Profile
Published date:
11/06/2019
Excerpt:
Pts are enrolled in sequential cohorts to receive durvalumab (fixed dose at 1500 mg) and dose escalation of lenalidomide...to characterize safety, efficacy and antitumor activity….Detectable levels of PD-L1 but low levels of ICOS are observed in responding pts vs. high PD-L1 and ICOS levels in non-responders.
DOI:
https://doi.org/10.1182/blood-2019-126358
Trial ID:
